Drug Trial Radar · NCT00037050
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
Last checked: Nov 19, 2026Latest source record: Sep 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
739
Actual
Start
Apr 2002
Primary completion
Not stated
Study completion Jul 2005
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 15, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
Conditions
- Bacterial Infections
- Gram-Positive Bacterial Infections
- Bacteremia
Interventions
LinezolidDrug
VancomycinDrug
OxacillinDrug
DicloxacillinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The empiric treatment of patients with complicated skin and skin structure infections (cSSSI) related to an indwelling catheter;
- The empiric treatment of patients with gram-positive catheter-related bloodstream infections.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.